Cargando…

Discovery of a SHP2 Degrader with In Vivo Anti-Tumor Activity

Src homology 2 domain-containing phosphatase 2 (SHP2) is an attractive target for cancer therapy due to its multifaceted roles in both tumor and immune cells. Herein, we designed and synthesized a novel series of proteolysis targeting chimeras (PROTACs) using a SHP2 allosteric inhibitor as warhead,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Jinmin, Bai, Yunpeng, Miao, Yiming, Qu, Zihan, Dong, Jiajun, Zhang, Ruo-Yu, Aggarwal, Devesh, Jassim, Brenson A., Nguyen, Quyen, Zhang, Zhong-Yin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10574094/ https://www.ncbi.nlm.nih.gov/pubmed/37836790 http://dx.doi.org/10.3390/molecules28196947

Ejemplares similares

Discovery of a selective TC-PTP degrader for cancer immunotherapy
por: Miao, Jinmin, et al.
Publicado: (2023)

SHP2 phosphatase as a novel therapeutic target for melanoma treatment
por: Zhang, Ruo-Yu, et al.
Publicado: (2016)

SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
por: Chen, Hao, et al.
Publicado: (2020)

Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
por: Chen, Hao, et al.
Publicado: (2022)

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
por: Zeng, Li-Fan, et al.
Publicado: (2014)

Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
por: Yu, Zhi-Hong, et al.
Publicado: (2014)

Discovery of a Novel Inhibitor of the Protein Tyrosine Phosphatase Shp2
por: Chen, Chuan, et al.
Publicado: (2015)

SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo
por: Hu, ZhongQian, et al.
Publicado: (2017)

Functions of Shp2 in cancer
por: Zhang, Jie, et al.
Publicado: (2015)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Effect of artemisinin on proliferation and apoptosis-related protein expression in vivo and in vitro
por: Chen, Jiajun, et al.
Publicado: (2018)

Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells
por: Raveendra-Panickar, Dhanya, et al.
Publicado: (2021)

The Discovery of Potent SHP2 Inhibitors with Anti-Proliferative Activity in Breast Cancer Cell Lines
por: Ghemrawi, Rose, et al.
Publicado: (2022)

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors
por: Gebregiworgis, Teklab, et al.
Publicado: (2021)

SHP2 is involved in the occurrence, development and prognosis of cancer
por: Li, Shu, et al.
Publicado: (2023)

Nuclear Receptor SHP: A Critical Regulator of miRNA and lncRNA Expression and Function
por: Song, Yongfeng, et al.
Publicado: (2017)

Treg-specific deletion of the phosphatase SHP-1 impairs control of inflammation in vivo
por: Gu, QinLei, et al.
Publicado: (2023)

The orphan nuclear receptor SHP regulates ER stress response by inhibiting XBP1s degradation
por: Sun, Shengyi, et al.
Publicado: (2019)

Shp2 Knockdown and Noonan/LEOPARD Mutant Shp2–Induced Gastrulation Defects
por: Jopling, Chris, et al.
Publicado: (2007)

Sidestepping SHP2 inhibition
por: Popescu, Bogdan, et al.
Publicado: (2023)

Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis
por: Liu, Xia, et al.
Publicado: (2011)

Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
por: Xu, Xiaozheng, et al.
Publicado: (2021)

Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization
por: Buck, Sara J. S., et al.
Publicado: (2022)

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
por: Franciosa, Giulia, et al.
Publicado: (2023)

Exploration of T cell immune responses by expression of a dominant-negative SHP1 and SHP2
por: Taylor, Julia, et al.
Publicado: (2023)

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
por: Bunda, Severa, et al.
Publicado: (2015)

Toward a Treatment of Cancer: Design and In Vitro/In Vivo Evaluation of Uncharged Pyrazoline Derivatives as a Series of Novel SHP2 Inhibitors
por: Dai, Jiajia, et al.
Publicado: (2022)

Study on the SHP2-Mediated Mechanism of Promoting Spermatogenesis Induced by Active Compounds of Eucommiae Folium in Mice
por: Mu, Hailong, et al.
Publicado: (2022)

Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2
por: Kim, Jenny Y., et al.
Publicado: (2020)

A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
por: Song, Yihui, et al.
Publicado: (2021)

SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses
por: Christofides, Anthos, et al.
Publicado: (2022)

Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development
por: Deng, Rong, et al.
Publicado: (2015)

Skeletal malformation and the SHP-2 pathway
Publicado: (2011)

Shp1 in Solid Cancers and Their Therapy
por: Varone, Alessia, et al.
Publicado: (2020)

The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42
por: Tien, Sui-Chih, et al.
Publicado: (2016)

PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2
por: Xu, Xiaozheng, et al.
Publicado: (2020)

Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect
por: Sun, Ziying, et al.
Publicado: (2022)

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved “backdoor” cysteine
por: Yarnall, Matthew T.N., et al.
Publicado: (2022)

Targeted Protein Degradation: An Important Tool for Drug Discovery for “Undruggable” Tumor Transcription Factors
por: Dai, Mengyuan, et al.
Publicado: (2022)

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Hematopoietic Progenitor Hyperproliferation and Malignant Disease In Vivo
por: Nabinger, Sarah C., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rrd15nfip2n82f6r0kchbvtrgf